Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

A federal judge's ruling essentially blocks compound pharmacies from selling less-expensive, unapproved versions of Ozempic ...

Owned by Vietnam’s wealthiest man, VinFast is more immune to not making a profit. On Thursday, the company reported it lost ...

The strategy was also overweight healthcare and industrials thanks to pharmaceutical picks such as Novo Nordisk NVO and aerospace companies like Airbus. The strategy's focus on multinational ...